Photo from Day One Biopharmaceuticals/LinkedIn
Jul 27, 2024, 22:01
Day One Biopharmaceuticals announces a new ex-U.S. licensing agreement with Ipsen to commercialize tovorafenib
Day One Biopharmaceuticals shared a post on LinkedIn:
”We are pleased to announce a new ex-U.S. licensing agreement with Ipsen to commercialize tovorafenib. This collaboration highlights our shared commitment to bring novel therapeutics to patients worldwide who have limited treatment options. Learn more.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 23:35
Nov 13, 2024, 23:33
Nov 13, 2024, 23:28
Nov 13, 2024, 23:26
Nov 13, 2024, 23:22
Nov 13, 2024, 23:18
Nov 13, 2024, 19:25